--- title: "Obesity & GLP-1 Therapeutics Industry" description: "190 SEC filers are classified under the Standard Industrial Classification code that describes the obesity & glp-1 therapeutics industry." canonical: https://www.getswoopr.com/stocks/industries/health-care/obesity-and-glp-1-therapeutics/ source: "Swoopr Investment: https://www.getswoopr.com" --- # Obesity & GLP-1 Therapeutics Industry ## Direct Answer 190 SEC filers are classified under the Standard Industrial Classification code that describes the obesity & glp-1 therapeutics industry, and their latest annual reports show $454.1 billion of combined revenue and a median operating margin of -339.4%. Investors should still evaluate its revenue model, industry-specific KPIs, valuation framework and the risks that can change the group's economics. ## Industry Overview Obesity and GLP-1 therapeutics companies develop and sell injectable and oral drugs that reduce appetite and weight and treat type 2 diabetes. Demand is very large and supply, payer coverage and competition are the main constraints. The first numbers to compare across companies here are prescriptions and net price, supply and manufacturing capacity and pipeline and trial results. ## Key Industry Metrics - **Prescriptions and net price**: Number of prescriptions and price received after rebates. Volume shows adoption, and net price shows how much coverage and competition reduce it. - **Supply and manufacturing capacity**: Ability to produce enough injectable or oral drug. Capacity limits can cap sales when demand exceeds supply. - **Pipeline and trial results**: Next-generation candidates and their trial data, including weight loss and outcomes. Results determine future competitiveness. - **Payer coverage**: Whether insurers and Medicare pay for weight-loss use. Coverage decisions largely determine how many patients can access treatment. - **Share among incretin drugs**: Portion of prescriptions in the class going to a company's drug. It shows competitive position in a market dominated by few products. ## Primary Macro Drivers - **Obesity prevalence and demand**: A large and rising share of adults with obesity means a large pool of potential patients, so demand shows up in prescriptions. - **Payer and Medicare coverage**: Whether insurers and Medicare pay for weight-loss use decides how many patients can afford treatment, which moves prescriptions and net price. - **Supply expansion**: Plants must make large volumes of injectables, so more capacity lets more patients start treatment and eases shortages. - **Cardiovascular and other outcome data**: Trials that show fewer heart attacks and other outcomes can widen labels and coverage, lifting prescriptions over time. ## Major Risks - **Competition and pricing pressure**: Newer entrants and large rivals compete on efficacy, dosing and price, which can lower net price per prescription; watch share among incretin drugs and pricing. - **Coverage limits**: Insurers and employers may limit coverage because of high cost, which caps patient starts; watch coverage decisions and prescription trends. - **Safety signals**: New findings on side effects could lead to label changes or lower prescribing; watch regulator communications and long-term data. - **Compounded copies and supply issues**: Pharmacies mixing their own versions can take sales and raise safety questions, while shortages limit patient starts; watch supply and regulatory actions. ## Industry Characteristics | Characteristic | Profile | | --- | --- | | Cyclicality | Defensive | | Capital Intensity | Medium | | Regulatory Intensity | High | | Industry Maturity | Growth | | Geographic Importance | U.S. / Global | ## Obesity & GLP-1 Therapeutics Filers in the SEC Record 190 companies with annual reports in the dataset are classified by the SEC in the Standard Industrial Classification code 2834. Their latest fiscal years end between 2022 and 2026, and together they reported $454.1 billion of revenue. Median revenue growth over the prior year was 11.1%. Median operating margin was -339.4% and median net margin -202.0%. Median total liabilities were 40% of total assets, and 40 of 190 reported a profit in their latest year. | Company | Revenue | Growth | Operating margin | Net margin | Year | | --- | --- | --- | --- | --- | --- | | [Johnson & Johnson](https://www.getswoopr.com/stocks/companies/johnson-and-johnson/) | $94.2 billion | 6.0% | n/a | 28.5% | FY 2025 | | [Eli Lilly & Co](https://www.getswoopr.com/stocks/companies/eli-lilly/) | $65.2 billion | 44.7% | n/a | 31.7% | FY 2025 | | [Pfizer Inc](https://www.getswoopr.com/stocks/companies/pfizer/) | $62.6 billion | -1.6% | n/a | 12.4% | FY 2025 | | [Abbvie Inc.](https://www.getswoopr.com/stocks/companies/abbvie/) | $61.2 billion | 8.6% | 24.6% | 6.9% | FY 2025 | | [Bristol Myers Squibb Co](https://www.getswoopr.com/stocks/companies/bristol-myers-squibb/) | $48.2 billion | -0.2% | n/a | 14.6% | FY 2025 | | [Abbott Laboratories](https://www.getswoopr.com/stocks/companies/abbott-laboratories/) | $44.3 billion | 5.7% | 18.2% | 14.7% | FY 2025 | | [Viatris Inc](https://www.getswoopr.com/stocks/companies/viatris/) | $14.3 billion | -3.0% | -18.6% | -24.6% | FY 2025 | | [Vertex Pharmaceuticals Inc / Ma](https://www.getswoopr.com/stocks/companies/vertex-pharmaceuticals/) | $12.0 billion | 8.9% | 34.8% | 32.9% | FY 2025 | The 8 largest of 190 by revenue. Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. A company's SIC code reflects its main business as the SEC records it, so it can differ from how an index provider or analyst classifies the company, and a diversified group appears under only one code. ## Where to Go Next The Obesity & GLP-1 Therapeutics guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company. ### More in Health Care - [Health Care sector overview](https://www.getswoopr.com/stocks/industries/health-care/) - [Oncology Biotechnology](https://www.getswoopr.com/stocks/industries/health-care/oncology-biotechnology/) - [Neuroscience Biotechnology](https://www.getswoopr.com/stocks/industries/health-care/neuroscience-biotechnology/) - [Oncology Pharmaceuticals](https://www.getswoopr.com/stocks/industries/health-care/oncology-pharmaceuticals/) - [mRNA Therapeutics](https://www.getswoopr.com/stocks/industries/health-care/mrna-therapeutics/) - [Ophthalmic Devices](https://www.getswoopr.com/stocks/industries/health-care/ophthalmic-devices/) - [Metabolic Disease Biotechnology](https://www.getswoopr.com/stocks/industries/health-care/metabolic-disease-biotechnology/) - [Ophthalmology Pharmaceuticals](https://www.getswoopr.com/stocks/industries/health-care/ophthalmology-pharmaceuticals/) - [Medicare Advantage](https://www.getswoopr.com/stocks/industries/health-care/medicare-advantage/) ### Put it to work - [How to analyze a stock](https://www.getswoopr.com/stocks/how-to-analyze-a-stock/) - [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/) - [Company research](https://www.getswoopr.com/stocks/companies/) - [All industries](https://www.getswoopr.com/stocks/industries/) ## Frequently Asked Questions What are the main KPIs for the Obesity & GLP-1 Therapeutics industry? Key performance indicators for the Obesity & GLP-1 Therapeutics industry include: Prescriptions and net price, Supply and manufacturing capacity, Pipeline and trial results, Payer coverage, Share among incretin drugs. Which matter most depends on the company's model, so compare them across several companies rather than relying on one. How cyclical is the Obesity & GLP-1 Therapeutics industry? The Obesity & GLP-1 Therapeutics industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions. What are the biggest risks in the Obesity & GLP-1 Therapeutics industry? The primary risks for Obesity & GLP-1 Therapeutics companies include: Competition and pricing pressure, Coverage limits, Safety signals, Compounded copies and supply issues. Investors should assess each company's exposure to these factors and its track record of navigating them. **[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)** Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).